Atherosclerosis, Coronary Artery Disease
Conditions
Keywords
Biological Markers, Multidetector Computed Tomography
Brief summary
Coronary artery disease (CAD) is the leading cause of morbidity and mortality in developed countries. In addition, many patients suffer from valvular and aortic disease. Although various tools are available to identify patients with cardiovascular (CV) disease at risk for major adverse cardiac events (MACE), the identification of these patients remains a clinical challenge. One promising avenue is the use of different serum biomarkers involved in atherothrombosis which could provide an easy and cost-effective step in risk stratification.
Interventions
BIOLOGICALVenous blood sampling prior to CCTA.
Sponsors
Maastricht University Medical Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
* Patients referred from the Cardiology clinic for routine CCTA.
Exclusion criteria
* Pregnancy * Severe renal insufficiency * Severe allergy to contrast medium * Inability to obtain informed consent * Age below 18 years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Data registration of patients undergoing CCTA and given written informed consent. | 15 years. |
| To detect these patients for cardiovascular disease and Long term CV outcome (MACE). | 15 years. |
Secondary
| Measure | Time frame |
|---|---|
| The relationship of novel blood biomarkers with CCTA findings. | 15 years. |
| The predictive value of these biomarkers to predict CAD in patients undergoing CCTA. | 15 years. |
| The prognostic value of these biomarkers (in combination) to predict MACE. | 15 years. |
Countries
Netherlands
Contacts
Primary ContactBas Kietselaer, MD, PhD
Backup ContactSibel Altintas, MD
Outcome results
None listed